Skip to main content
Advertisement
Advertisement

TBPH

TBPH logo

Theravance Biopharma, Inc.

17.03
USD
Sponsored
0.00
0.00%
Sep 23, 15:50 UTC -4
Closed
exchange

After-Market

17.05

+0.02
+0.09%

TBPH Earnings Reports

Positive Surprise Ratio

TBPH beat 18 of 43 last estimates.

42%

Next Report

Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$22.07M
/
$0.17
Implied change from Q2 26 (Revenue/ EPS)
+6.44%
/
--
Implied change from Q3 25 (Revenue/ EPS)
+10.39%
/
+142.86%

Theravance Biopharma, Inc. earnings per share and revenue

On Aug 10, 2026, TBPH reported earnings of 0.00 USD per share (EPS) for Q2 26, missing the estimate of 0.05 USD, resulting in a -92.16% surprise. Revenue reached 20.73 million, compared to an expected 22.03 million, with a -5.91% difference. The market reacted with a -0.12% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of 0.17 USD, with revenue projected to reach 22.07 million USD, implying an -- of --% EPS, and increase of 6.44% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Theravance Biopharma, Inc. reported EPS of $0.00, missing estimates by -92.16%, and revenue of $20.73M, -5.91% below expectations.
The stock price moved down -0.12%, changed from $16.93 before the earnings release to $16.91 the day after.
The next earning report is scheduled for Nov 09, 2026.
Based on 7 analysts, Theravance Biopharma, Inc. is expected to report EPS of $0.17 and revenue of $22.07M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement